相关实验视频

Updated: Jun 13, 2025

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis

Published on: May 9, 2025

肺纤维化在沙尔科发病中的病例. 抗纤维素药有没有地方?

Karol Bączek¹, Wojciech Jerzy Piotrowski¹

¹Department of Pneumology, Medical University of Łódź, Łódź, Poland.

Frontiers in pharmacology

|September 16, 2024

概括

抗纤维素药物在治疗沙尔科病患者的肺纤维化方面表现有前途,这是导致死亡的主要原因. 需要进一步的研究来确认它们的有效性,并优化这种复杂的炎症性疾病的治疗策略.

科学领域:

肺部医学肺部医学
类风湿病学类风湿病学
药理学药理学是指药理学的学科.

背景情况:

沙丘病是一个炎症性疾病,影响多个器官,主要是肺部.
肺纤维化,在多达20%的沙尔科毒症病例中是一种并发症,显著增加了死亡率.
目前的治疗重点是抗炎方法,但抗纤维菌疗法正在出现.

研究的目的:

审查使用抗纤维素药物在治疗纤维素类瘤症方面的证据.
评估抗纤维素药物的潜在好处和缺点在肉类发病.
为了强调在这个治疗领域需要进一步的研究.

主要方法:

关于在型硬化症中使用抗纤维菌药物的理论和经验证据的审查.
分析现有关于宁泰达尼布和皮尔费尼在纤维性肺部疾病中的研究.
讨论抗纤维素药在慢性炎症的背景下抗纤维素药的作用.

主要成果:

丁丁达尼布在渐进性纤维化间歇性肺部疾病 (PF-ILD) 中显示出有前途,包括沙尔科病.
皮尔芬尼已在纤维性肉类发病中表现出潜在的潜力,但由于样本规模小,研究结果尚不确定.
抗纤维素药物代表了纤维素类沙丘病的潜在新疗法途径.

结论:

抗纤维素药物为纤维素性沙丘症提供了潜在的治疗策略.
更多的随机对照试验是必要的,以确定抗纤维素药物在沙尔科毒症的疗效.
需要进行进一步的研究,以改善患者的治疗结果,并推进与沙尔科毒症相关的纤维化治疗模式.

关键词:

抗纤维菌剂是一种抗纤维菌剂.有纤维化的纤维化.这种状况是什么? granuloma granuloma.任天堂Danib 在线播放皮尔芬尼多尼的使用.这种类型的麻症是有毒的.

更多相关视频

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

A Mouse Model of Pulmonary Fibrosis Induced by Nasal Bleomycin Nebulization

Published on: January 20, 2023

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...

COPD: Management Using Bronchodilators and Corticosteroids

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...

Cystic Fibrosis: Management

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...

Drugs Used in Lower Respiratory Disorders: Overview

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...